CN111387194A - Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof - Google Patents
Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof Download PDFInfo
- Publication number
- CN111387194A CN111387194A CN202010112191.6A CN202010112191A CN111387194A CN 111387194 A CN111387194 A CN 111387194A CN 202010112191 A CN202010112191 A CN 202010112191A CN 111387194 A CN111387194 A CN 111387194A
- Authority
- CN
- China
- Prior art keywords
- compound
- infection
- product
- novel coronavirus
- disinfection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A01N43/14—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
- A01N43/16—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Birds (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Textile Engineering (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Agronomy & Crop Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof, belonging to the technical field of medicines. The effective components of the compound comprise epigallocatechin gallate (EGCG) and a structure modifier thereof, ECG and GCG analogues, the effective use concentration range is 1-1000 ug/ml or 1-1000 ug/g, and a product containing the compound can be used for preventing and treating the infection of the novel coronavirus, and specifically weakening the infection capacity of the novel coronavirus, thereby preventing and treating the infection of the novel coronavirus and reducing the human-borne risk.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof.
Background
The novel coronavirus pneumonia, called new coronavirus pneumonia for short, is an acute infectious disease and is caused by 2019 novel coronavirus (2019-nCoV) infection. After a person is infected with the novel coronavirus, the main symptoms include respiratory symptoms, fever, cough, shortness of breath, dyspnea, etc., and in more severe cases, the infection may cause pneumonia, severe acute respiratory syndrome, renal failure, and even death. At present, aiming at diseases caused by novel coronavirus, effective antiviral drugs aiming at pathogens are lacked, and isolation treatment and symptomatic support treatment are mainly used. Meanwhile, for the vast susceptible population, the existing protective products such as masks, alcohol-containing disinfection products and the like are all in broad-spectrum protection, and no protective products which are efficient and can specifically block virus infection exist in the market. Therefore, by utilizing modern scientific technology, the development effect is clear, and the product with high efficiency and specificity for preventing and treating the new coronavirus infection meets the public requirements and has extremely important practical significance and social significance.
Disclosure of Invention
Based on the current situation that the existing protective articles can only carry out broad-spectrum protection and do not have high-efficiency and specific protective products for novel coronavirus, the invention aims to provide a compound for efficiently and specifically preventing and treating virus infection, in particular to a compound for efficiently and specifically preventing and treating novel coronavirus infection, which can weaken the infection capacity of the novel coronavirus, thereby efficiently and specifically preventing and treating the infection of the novel coronavirus and reducing the human-borne risk.
In order to realize the purpose, the invention is realized by the following technical scheme:
the effective component of the compound is prepared from tea extract, and the main component of the compound comprises epigallocatechin gallate (EGCG) and a structure modifier thereof, ECG and GCG analogues.
The compound is applied to the preparation of medicines, medical equipment, health products or sterilizing products with the function of preventing and treating the infection of the new coronavirus.
Further preferably, the compound is used in an effective concentration range of 1-1000 ug/ml or 1-1000 ug/g.
Further preferably, the form of the medicine, medical equipment, health product or disinfection product comprises tablets, granules, hard capsules, soft capsules, oral liquid, powder, mixture, pills, dropping pills, spray, aerosol, powder spray, soap, toothpaste, mouthwash, mask, hand cream, eye drops, hand sanitizer, disinfectant gel, wet paper towel, laundry detergent and mask.
The invention has the beneficial effects that:
the invention provides a compound capable of specifically targeting novel coronavirus, the effective components of the compound comprise epigallocatechin gallate (EGCG) and a structure modifier thereof, ECG and GCG analogues, and the effective use concentration range is 1-1000 ug/ml or 1-1000 ug/g. The compound is used for product development, and the developed product is used for preventing and treating infection of new coronavirus, and can specifically weaken the infection capacity of the new coronavirus, so that the infection of the new coronavirus is prevented and treated, and the human-borne risk is reduced.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, preferred embodiments of the present invention will be described in detail below to facilitate understanding of the skilled person.
The invention relates to a product such as a medicine, a medical appliance, a health care product or a sterilizing product and the like containing effective components of a compound with high efficiency and specificity for preventing and treating new coronavirus infection.
Example 1
EGCG in an effective concentration range is added into the disinfection gel, and the added disinfection gel can effectively reduce the residue of new coronavirus on the surface of skin, thereby reducing the infection risk.
Example 2
EGCG in an effective concentration range is added into the interlayer of the mask, so that new coronavirus outside the mask is effectively isolated from entering a respiratory system in a respiratory mode.
Example 3
The compound in the effective concentration range is added into the eye drops, the new coronavirus enters the conjunctiva of the eye along with touching the eye, and the eye drops are used to effectively remove the virus existing on the conjunctiva and prevent and treat contact infection.
Example 4
The compound in the effective concentration range is added into the disinfectant and is released into the environment in a spraying mode, so that the infection capacity of the new coronavirus in the environment is reduced, and the infection risk is reduced.
Example 5
The wet tissue is added with the compound within the effective concentration range, and the hands are wiped to prevent the residue of the new coronavirus on the hands when people go out, so that the infection risk is reduced.
The invention provides a compound capable of specifically targeting a novel coronavirus, and product development is carried out by utilizing the compound. The effective component of the compound is prepared from tea extract, and the main component comprises epigallocatechin gallate EGCG and its structure modifier, ECG, GCG analogue. The effective component can specifically bind with novel coronavirus surface immunogen (ligand) in molecular interaction research, and reduce the binding response value of ligand and novel coronavirus receptor (ACE 2) in effective concentration range of the compound. The compound can specifically weaken the infection capacity of the new coronavirus, thereby preventing and treating the infection of the new coronavirus and reducing the human-borne risk.
Finally, it is noted that the above-mentioned preferred embodiments illustrate rather than limit the invention, and that, although the invention has been described in detail with reference to the above-mentioned preferred embodiments, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the scope of the invention as defined by the appended claims.
Claims (4)
1. A compound for efficiently and specifically preventing and treating virus infection is characterized in that: the effective component of the compound is prepared from tea extract, and the main component comprises epigallocatechin gallate EGCG and a structure modifier thereof, ECG and GCG analogues.
2. Use of a compound according to claim 1 for the preparation of a medicament, medical device, health product or disinfection product for the prevention and treatment of a new coronavirus infection.
3. The compound of claim 1 or 2, wherein: the effective using concentration range of the compound is 1-1000 ug/ml or 1-1000 ug/g.
4. Use of a compound according to claim 2 or 3 for the preparation of a medicament, medical device, health product or disinfection product for the prevention and treatment of new coronavirus infection, characterized in that: the form of the medicine, the medical equipment, the health care product or the disinfection and killing product comprises tablets, granules, hard capsules, soft capsules, oral liquid, powder, mixture, pills, dropping pills, spraying agents, aerosol, powder spray, soap, toothpaste, mouthwash, facial masks, hand cream, eye drops, hand sanitizer, disinfectant solution, disinfection gel, wet tissues, laundry detergent and masks.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010112191.6A CN111387194A (en) | 2020-02-24 | 2020-02-24 | Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010112191.6A CN111387194A (en) | 2020-02-24 | 2020-02-24 | Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111387194A true CN111387194A (en) | 2020-07-10 |
Family
ID=71412038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010112191.6A Pending CN111387194A (en) | 2020-02-24 | 2020-02-24 | Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111387194A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112753827A (en) * | 2021-01-25 | 2021-05-07 | 昆明生物制造研究院有限公司 | Fermented brown sugar ginger tea and preparation method thereof |
| CN112772808A (en) * | 2021-01-25 | 2021-05-11 | 昆明生物制造研究院有限公司 | Lucid ganoderma and blueberry compound fermented beverage and preparation method thereof |
| CN112889932A (en) * | 2021-01-25 | 2021-06-04 | 昆明生物制造研究院有限公司 | Preparation method of zero-trans-fatty acid walnut non-dairy creamer |
| CN115569196A (en) * | 2020-02-26 | 2023-01-06 | 上海科技大学 | Application of polyphenol substances in resisting coronavirus |
| CN116077560A (en) * | 2023-01-31 | 2023-05-09 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | Application of EGCG composition in preparation of medicines for treating novel coronaviruses |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535012A (en) * | 2016-01-27 | 2016-05-04 | 中国人民解放军疾病预防控制所 | Broad-spectrum virus infection inhibitor |
| CN105687226A (en) * | 2016-01-27 | 2016-06-22 | 中国人民解放军疾病预防控制所 | Preparation for inhibiting coronavirus infections |
| CN106491586A (en) * | 2016-10-26 | 2017-03-15 | 上海海洋大学 | Application of the Epigallo-catechin gallate (EGCG) as preventing and treating prawn white spot syndrome medicine |
-
2020
- 2020-02-24 CN CN202010112191.6A patent/CN111387194A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535012A (en) * | 2016-01-27 | 2016-05-04 | 中国人民解放军疾病预防控制所 | Broad-spectrum virus infection inhibitor |
| CN105687226A (en) * | 2016-01-27 | 2016-06-22 | 中国人民解放军疾病预防控制所 | Preparation for inhibiting coronavirus infections |
| CN106491586A (en) * | 2016-10-26 | 2017-03-15 | 上海海洋大学 | Application of the Epigallo-catechin gallate (EGCG) as preventing and treating prawn white spot syndrome medicine |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115569196A (en) * | 2020-02-26 | 2023-01-06 | 上海科技大学 | Application of polyphenol substances in resisting coronavirus |
| CN112753827A (en) * | 2021-01-25 | 2021-05-07 | 昆明生物制造研究院有限公司 | Fermented brown sugar ginger tea and preparation method thereof |
| CN112772808A (en) * | 2021-01-25 | 2021-05-11 | 昆明生物制造研究院有限公司 | Lucid ganoderma and blueberry compound fermented beverage and preparation method thereof |
| CN112889932A (en) * | 2021-01-25 | 2021-06-04 | 昆明生物制造研究院有限公司 | Preparation method of zero-trans-fatty acid walnut non-dairy creamer |
| CN116077560A (en) * | 2023-01-31 | 2023-05-09 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | Application of EGCG composition in preparation of medicines for treating novel coronaviruses |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111387194A (en) | Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof | |
| CN111358781A (en) | Application of ellagic acid in preventing and treating novel coronavirus infection | |
| US6034133A (en) | Use of a virucidal hand lotion to prevent the spread of rhinovirus colds | |
| US4767788A (en) | Glutaric acid virucidal processes and compositions | |
| Schütz et al. | Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures | |
| EA018138B1 (en) | Use of iota-carrageenan as antiviral ingredient | |
| JP5470047B2 (en) | Antiviral compositions and methods of use | |
| IL165980A (en) | Plant containing composition for treating herpes virus and other infectious diseases | |
| CN106668832B (en) | Application of polypeptide in preparation of medicine for treating enterovirus infection | |
| Alhouri et al. | Possible side effects of using detergents during the Covid19 pandemic in Syria | |
| JP2017522330A (en) | Treatment and prevention of the common cold using povidone iodine | |
| EP0198061A1 (en) | Use of compositions comprising sulfosuccinates for the manufacture of a medicament for preventing or treating viral infections | |
| CN108371191A (en) | A kind of air antiseptic and its preparation method and application | |
| CN111358779A (en) | Application of amygdalol A in preventing and treating novel coronavirus infection | |
| WO2021212269A1 (en) | Application of ellagic acid in preventing and treating novel coronavirus infection | |
| WO2021212270A1 (en) | Application of amaronol a in prevention and treatment of novel coronavirus infection | |
| US20060287364A1 (en) | Methods of prevention of infection with HIV/AIDS, venereal disease and influenza | |
| WO2021202332A1 (en) | Aqueous formulations containing povidone iodine for effective treatment and prevention of virus infections | |
| EP3888629A1 (en) | Composition for treatment or prevention of a virus infection | |
| US11266145B2 (en) | Compositions comprising protocatechuic acid and methods of use | |
| CN111450297A (en) | Marine fucoidin herbal atomizing agent and preparation method thereof | |
| JPH06505733A (en) | Use of benzimidazole anthelmintics in the treatment of microsporidiosis | |
| Misra | A short review on important drugs under clinical trial against Covid-19 | |
| RU2135160C1 (en) | Composition for nasal cavity rinsing | |
| BRPI0408441A (en) | 2- (butyl-1-sulfonylamino) -n- [1 (r) - (6-methoxy-pyridin-3-yl) -propyl] -benzamide, as a medicament, as well as pharmaceutical preparations containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200710 |